
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is a promising company with strong revenue growth and a successful product launch. However, potential risks such as competition and regulatory changes should be taken into consideration by investors before purchasing stock in the company.
Bears say
Beta Bionics is showing promising results in their Q1 report, reporting better-than-expected new patient additions, increased gross margin, and a progressing sales force expansion. However, there are concerns regarding competition from devices and therapeutics, potential risks associated with the clinical and regulatory processes for their future products, and reimbursement rate cuts. While their strategy of targeting the pharmacy channel may support future revenue growth, there is still a risk of slower sales force ramp and pharmacy access expansion. Additionally, their innovation pipeline includes a promising patch pump and bihormonal pump, but there are still concerns about unmet needs and competition in the market. Overall, there is potential for growth in the long term, but there are also risks and uncertainties that warrant a negative outlook on the stock at this time.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares